Layoff
Mar 2022BridgeBio confirmed layoffs and restructuring amid market pressure and clinical setbacks; the company did not disclose the exact number of affected employees.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
BridgeBio is a commercial-stage biopharmaceutical company focused on genetic conditions and rare diseases, organized around a decentralized hub-and-spoke model. Its lead marketed product is Attruby (acoramidis) for ATTR-CM.
Primary product
Attruby (acoramidis)
Founded
2015
Headquarters
3160 Porter Drive, Suite 250, Palo Alto, CA 94304, USA
Team size
501-1000
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Genetic medicines / rare disease biopharmaceuticals
Offices
Palo Alto, California, United States (HQ)
San Francisco, California, United States (office / hybrid roles)
San Carlos, California, United States (role/site location in job postings)
Business model
Funding
Stage
public
Total raised
$5.2B
Latest round
Preferred equity financing · Jul 2026
Latest amount
$933.9M
Jul 2026 · Sixth Street / HealthCare Royalty
Jul 2026 · Sixth Street
People & investors
Leadership
Chief Executive Officer and Founder
President and Chief Financial Officer
Chief Scientific Officer
Work & culture
Patient-first, intellectually independent, high-urgency, and data-driven; the company emphasizes challenging convention and letting science speak.
Work style
Flexible
Compensation
Public job posts show California base salary bands such as about $94.8k-$105.2k for Research Associate II and $245k-$275k for Senior Director, Training and Learning Excellence, alongside market-leading pay, equity, and financial reward signals.
Benefits
market-leading pay
comprehensive healthcare
flexible working model
401(k) with employer match
employee stock purchase program (ESPP)
Product & market
Pricing
Specialty prescription-drug pricing with payer reimbursement; some assets are also monetized through licensing and royalties.
Differentiators
- —Decentralized hub-and-spoke model for speed and scalability
- —Focus on genetic diseases with clear genetic drivers
- —Commercial-stage with approved products already on market
- —First/best-in-class positioning for several programs
- —Centralized shared clinical, regulatory, and commercial capabilities
- —Deep academic-partnership sourcing of early science
- —Ex-U.S. licensing and royalty monetization to fund growth
- —Patient-first culture and rapid execution
Technology
Workday
Scale & contact
Estimated revenue
$500M-$600M
Estimated monthly visits
46.2K
Traffic estimate as of Jul 2026
Signals & risks
Acquisition
Jan 2021BridgeBio completed its acquisition of the remaining Eidos Therapeutics shares, making Eidos a wholly owned subsidiary and bringing acoramidis commercialization in-house.
SourceLatest news
BridgeBio Pharma, Inc. · Jul 2026
BridgeBio said the FDA accepted the NDA for encaleret in ADH1 and gave a PDUFA target action date of May 8, 2027.
BridgeBio Pharma, Inc. · Jul 2026
BridgeBio reported published analyses in Circulation: Heart Failure suggesting kidney-protective effects of acoramidis in ATTR-CM patients.
BridgeBio Pharma, Inc. · Jul 2026
BridgeBio announced up to $1 billion of preferred equity led by Sixth Street with participation from HealthCare Royalty, supporting upcoming launches including BBP-418, encaleret, and infigratinib.
Open Positions
100 jobs at BridgeBio
Senior Director, Health Economics and Outcomes Research, International
On-siteMarket AccessSwitzerland Office3d ago
On-site